{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:44:57Z","timestamp":1789429497697,"version":"build-2803163510"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40266-024-01103-2","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:01:57Z","timestamp":1710176517000},"page":"339-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer\u2019s Disease Initiating Cholinesterase Inhibitors"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-2317","authenticated-orcid":false,"given":"Ashna","family":"Talwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satabdi","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abughosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2986","volume":"344","author":"J Rodda","year":"2012","unstructured":"Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ. 2012;344: e2986.","journal-title":"BMJ"},{"key":"1103_CR2","doi-asserted-by":"publisher","first-page":"1115721","DOI":"10.3389\/fphar.2023.1115721","volume":"14","author":"AI Foudah","year":"2023","unstructured":"Foudah AI, Devi S, Alam A, Salkini MA, Ross SA. Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer\u2019s disease in rats: mechanistic approach to prevent inflammation. Front Pharmacol. 2023;14:1115721.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1103_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1479-8301.2010.00310.x","volume":"10","author":"K Konishi","year":"2010","unstructured":"Konishi K, Hori K, Uchida H, Watanabe K, Tominaga I, Kimura M, et al. Adverse effects of anticholinergic activity on cognitive functions in Alzheimer\u2019s disease. Psychogeriatrics. 2010;10(1):34\u20138.","journal-title":"Psychogeriatrics"},{"key":"1103_CR4","unstructured":"Alzheimer\u2019s Association. 2022 Alzheimer\u2019s Disease Facts and Figures. Alzheimers Dement 2022;18."},{"issue":"2","key":"1103_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jalz.2010.03.016","volume":"7","author":"G Small","year":"2011","unstructured":"Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(2):177\u201384.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1103_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.amjmed.2006.08.036","volume":"120","author":"MR Farlow","year":"2007","unstructured":"Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer\u2019s disease. Am J Med. 2007;120(5):388\u201397.","journal-title":"Am J Med"},{"issue":"4","key":"1103_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00002512-199303040-00004","volume":"3","author":"M Feinberg","year":"1993","unstructured":"Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335\u201348.","journal-title":"Drugs Aging"},{"issue":"9","key":"1103_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/014107680009300903","volume":"93","author":"J Mintzer","year":"2000","unstructured":"Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J Roy Soc Med. 2000;93(9):457\u201362.","journal-title":"J Roy Soc Med."},{"issue":"5","key":"1103_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1474-4422(06)70421-5","volume":"5","author":"PM Doraiswamy","year":"2006","unstructured":"Doraiswamy PM, Husain MM. Anticholinergic drugs and elderly people: a no brainer? Lancet Neurol. 2006;5(5):379\u201380.","journal-title":"Lancet Neurol"},{"issue":"Suppl 21","key":"1103_CR10","first-page":"11","volume":"62","author":"LE Tune","year":"2001","unstructured":"Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11\u20134.","journal-title":"J Clin Psychiatry"},{"key":"1103_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3389\/fnins.2019.01309","volume":"13","author":"J L\u00f3pez-\u00c1lvarez","year":"2019","unstructured":"L\u00f3pez-\u00c1lvarez J, Sevilla-Llewellyn-Jones J, Ag\u00fcera-Ortiz L. Anticholinergic drugs in geriatric psychopharmacology. Front Neurosci. 2019;13:1309.","journal-title":"Front Neurosci"},{"issue":"4","key":"1103_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1103_CR13","first-page":"103","volume":"7","author":"CT Naugler","year":"2000","unstructured":"Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103\u20137.","journal-title":"Can J Clin Pharmacol"},{"issue":"2","key":"1103_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5414\/CPP46072","volume":"46","author":"P Gallagher","year":"2008","unstructured":"Gallagher P, Ryan C, Byrne S, Kennedy J, O\u2019Mahony D. STOPP (Screening Tool of Older Person\u2019s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72\u201383.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"1103_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721\u201332.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1103_CR16","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF. Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules. 2022;27(6):1816.","journal-title":"Molecules"},{"issue":"4","key":"1103_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/00019442-200307000-00009","volume":"11","author":"CJ Lu","year":"2003","unstructured":"Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry. 2003;11(4):458\u201361.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"1103_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","volume":"56","author":"KM Sink","year":"2008","unstructured":"Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56(5):847\u201353.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"1103_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archinte.167.8.781","volume":"167","author":"SN Hilmer","year":"2007","unstructured":"Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781\u20137.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1103_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"JL Rudolph","year":"2008","unstructured":"Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508\u201313.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1103_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0091270006292126","volume":"46","author":"RM Carnahan","year":"2006","unstructured":"Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1103_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401\u20137.","journal-title":"JAMA Intern Med"},{"key":"1103_CR23","doi-asserted-by":"publisher","DOI":"10.2217\/1745509X.4.3.311","author":"M Boustani","year":"2008","unstructured":"Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008. https:\/\/doi.org\/10.2217\/1745509X.4.3.311.","journal-title":"Aging Health"},{"key":"1103_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2019.05.010","volume":"87","author":"G Lozano-Ortega","year":"2020","unstructured":"Lozano-Ortega G, Johnston KM, Cheung A, Wagg A, Campbell NL, Dmochowski RR, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020;87: 103885.","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"1103_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/gerona\/gln043","volume":"64","author":"JT Hanlon","year":"2009","unstructured":"Hanlon JT, Boudreau RM, Roumani YF, Newman AB, Ruby CM, Wright RM, et al. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci. 2009;64(4):492\u20138.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"1103_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1046\/j.1532-5415.2002.50254.x","volume":"50","author":"SL Gray","year":"2002","unstructured":"Gray SL, LaCroix AZ, Blough D, Wagner EH, Koepsell TD, Buchner D. Is the use of benzodiazepines associated with incident disability? J Am Geriatr Soc. 2002;50(6):1012\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"1103_CR27","first-page":"311","volume":"38","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Walker D, Kimura T, Aparasu RR. Prevalence and factors associated with cumulative anticholinergic burden among older long-stay nursing home residents with overactive bladder. Drugs Aging. 2021;38(4):311\u201326.","journal-title":"Drugs Aging"},{"issue":"5","key":"1103_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026391","volume":"9","author":"SM Szabo","year":"2019","unstructured":"Szabo SM, Gooch K, Schermer C, Walker D, Lozano-Ortega G, Rogula B, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5): e026391.","journal-title":"BMJ Open"},{"issue":"8","key":"1103_CR29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084\u201393.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"1103_CR30","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/jgs.15508","volume":"66","author":"L Heath","year":"2018","unstructured":"Heath L, Gray SL, Boudreau DM, Thummel K, Edwards KL, Fullerton SM, et al. Cumulative antidepressant use and risk of dementia in a prospective cohort study. J Am Geriatr Soc. 2018;66(10):1948\u201355.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1103_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s41669-020-00215-w","volume":"5","author":"G Lozano-Ortega","year":"2021","unstructured":"Lozano-Ortega G, Schermer CR, Walker DR, Szabo SM, Rogula B, Deighton AM, et al. Fall\/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder. Pharmacoecon Open. 2021;5(1):45\u201355.","journal-title":"Pharmacoecon Open."},{"key":"1103_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i90","volume":"352","author":"SL Gray","year":"2016","unstructured":"Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016;352: i90.","journal-title":"BMJ"},{"issue":"5","key":"1103_CR33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/jgs.17686","volume":"70","author":"YK Haddad","year":"2022","unstructured":"Haddad YK, Kakara R, Marcum ZA. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults. J Am Geriatr Soc. 2022;70(5):1450\u201360.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1103_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1049909118800281","volume":"36","author":"A Williams","year":"2019","unstructured":"Williams A, Sera L, McPherson ML. Anticholinergic burden in hospice patients with dementia. Am J Hosp Palliat Care. 2019;36(3):222\u20137.","journal-title":"Am J Hosp Palliat Care"},{"issue":"2","key":"1103_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40266-014-0230-0","volume":"32","author":"KE Mate","year":"2015","unstructured":"Mate KE, Kerr KP, Pond D, Williams EJ, Marley J, Disler P, et al. Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs Aging. 2015;32(2):159\u201367.","journal-title":"Drugs Aging"},{"issue":"3","key":"1103_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/jgs.14034","volume":"64","author":"CE Reppas-Rindlisbacher","year":"2016","unstructured":"Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: the effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492\u2013500.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"1103_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bcpt.13184","volume":"124","author":"YM Ah","year":"2019","unstructured":"Ah YM, Suh Y, Jun K, Hwang S, Lee JY. Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic Clin Pharmacol Toxicol. 2019;124(6):741\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1103_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JAD-180353","volume":"65","author":"ECK Tan","year":"2018","unstructured":"Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic burden and risk of stroke and death in people with different types of dementia. J Alzheimers Dis. 2018;65(2):589\u201396.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1103_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40266-018-00630-z","volume":"36","author":"AR Green","year":"2019","unstructured":"Green AR, Reifler LM, Bayliss EA, Weffald LA, Boyd CM. Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective cohort study. Drugs Aging. 2019;36(3):289\u201397.","journal-title":"Drugs Aging"},{"issue":"6","key":"1103_CR40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.amjopharm.2011.10.001","volume":"9","author":"R Bhattacharya","year":"2011","unstructured":"Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9(6):434\u201341.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"12","key":"1103_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/11584430-000000000-00000","volume":"27","author":"S Chatterjee","year":"2010","unstructured":"Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27(12):987\u201397.","journal-title":"Drugs Aging"},{"issue":"10","key":"1103_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40266-013-0104-x","volume":"30","author":"SD Sura","year":"2013","unstructured":"Sura SD, Carnahan RM, Chen H, Aparasu RR. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging. 2013;30(10):837\u201344.","journal-title":"Drugs Aging"},{"issue":"12","key":"1103_CR43","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/pds.4902","volume":"28","author":"KI Joung","year":"2019","unstructured":"Joung KI, Shin JY, Cho SI. Features of anticholinergic prescriptions and predictors of high use in the elderly: population-based study. Pharmacoepidemiol Drug Saf. 2019;28(12):1591\u2013600.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"1103_CR44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/ggi.13748","volume":"19","author":"LF Valladales-Restrepo","year":"2019","unstructured":"Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE. Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer\u2019s disease patients. Geriatr Gerontol Int. 2019;19(9):913\u20137.","journal-title":"Geriatr Gerontol Int"},{"issue":"5","key":"1103_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11096-013-9793-9","volume":"35","author":"EK Lee","year":"2013","unstructured":"Lee EK, Lee YJ. Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia. Int J Clin Pharm. 2013;35(5):711\u20138.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"1103_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40266-014-0227-8","volume":"32","author":"JB Palmer","year":"2015","unstructured":"Palmer JB, Albrecht JS, Park Y, Dutcher S, Rattinger GB, Simoni-Wastila L, et al. Use of drugs with anticholinergic properties among nursing home residents with dementia: a national analysis of Medicare beneficiaries from 2007 to 2008. Drugs Aging. 2015;32(1):79\u201386.","journal-title":"Drugs Aging"},{"issue":"6","key":"1103_CR47","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/gps.5084","volume":"34","author":"J Reinold","year":"2019","unstructured":"Reinold J, Palese F, Romanese F, Logroscino G, Riedel O, Pisa FE. Anticholinergic burden before and after hospitalization in older adults with dementia: increase due to antipsychotic medications. Int J Geriatr Psychiatry. 2019;34(6):868\u201380.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"1103_CR48","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jamda.2008.11.005","volume":"10","author":"A Kolanowski","year":"2009","unstructured":"Kolanowski A, Fick DM, Campbell J, Litaker M, Boustani M. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc. 2009;10(4):252\u20137.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"1103_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40266-018-0522-x","volume":"35","author":"AR Green","year":"2018","unstructured":"Green AR, Reifler LM, Boyd CM, Weffald LA, Bayliss EA. Medication profiles of patients with cognitive impairment and high anticholinergic burden. Drugs Aging. 2018;35(3):223\u201332.","journal-title":"Drugs Aging"},{"issue":"6","key":"1103_CR50","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/ageing\/afr102","volume":"40","author":"C Fox","year":"2011","unstructured":"Fox C, Livingston G, Maidment ID, Coulton S, Smithard DG, Boustani M, et al. The impact of anticholinergic burden in Alzheimer\u2019s dementia-the LASER-AD study. Age Ageing. 2011;40(6):730\u20135.","journal-title":"Age Ageing"},{"issue":"1","key":"1103_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/psyg.12291","volume":"18","author":"S Watanabe","year":"2018","unstructured":"Watanabe S, Fukatsu T, Kanemoto K. Risk of hospitalization associated with anticholinergic medication for patients with dementia. Psychogeriatrics. 2018;18(1):57\u201363.","journal-title":"Psychogeriatrics"},{"key":"1103_CR52","unstructured":"Centers for Medicare & Medicaid Services. Medicare Standard Analytical Files: Identifiable Data Files. Available at: http:\/\/www.cms.hhs.gov\/IdentifiableDataFiles\/02_StandardAnalyticalFiles.asp (Accessed Nov 2021)"},{"key":"1103_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5205","volume":"349","author":"SB De Gage","year":"2014","unstructured":"De Gage SB, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: case-control study. BMJ. 2014;349: g5205.","journal-title":"BMJ"},{"issue":"1","key":"1103_CR54","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1038\/s41598-021-82593-7","volume":"11","author":"SY Kang","year":"2021","unstructured":"Kang SY, Kim YJ, Jang W, Son KY, Park HS, Kim YS. Body mass index trajectories and the risk for Alzheimer\u2019s disease among older adults. Sci Rep. 2021;11(1):3087.","journal-title":"Sci Rep"},{"issue":"12","key":"1103_CR55","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495\u20139.","journal-title":"Int J Surg"},{"key":"1103_CR56","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2020. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2019."},{"issue":"1","key":"1103_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2137284","volume":"36","author":"RM Andersen","year":"1995","unstructured":"Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1\u201310.","journal-title":"J Health Soc Behav"},{"issue":"6","key":"1103_CR58","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1331\/JAPhA.2015.14288","volume":"55","author":"N Kachru","year":"2015","unstructured":"Kachru N, Carnahan RM, Johnson ML, Aparasu RR. Potentially inappropriate anticholinergic medication use in older adults with dementia. J Am Pharm Assoc (2003). 2015;55(6):603\u201312.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"7","key":"1103_CR59","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","volume":"55","author":"BJ Moore","year":"2017","unstructured":"Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index. Med Care. 2017;55(7):698\u2013705.","journal-title":"Med Care"},{"issue":"6","key":"1103_CR60","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","volume":"75","author":"DH Kim","year":"2020","unstructured":"Kim DH, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn RJ. Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data. J Gerontol A Biol Sci Med Sci. 2020;75(6):1120\u20135.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1103_CR61","unstructured":"SAS-STAT. SAS Institute, Inc. Cary, NC; 2001. Changes and Enhancements, Release 8.0."},{"issue":"12","key":"1103_CR62","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/j.1532-5415.2004.52563.x","volume":"52","author":"RM Carnahan","year":"2004","unstructured":"Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004;52(12):2082\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1103_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/ipm.2019.20","volume":"39","author":"RM Vaughan","year":"2022","unstructured":"Vaughan RM, Flynn R, Greene N. Anticholinergic burden of patients with dementia attending a Psychiatry of Later Life service. Ir J Psychol Med. 2022;39(1):39\u201344.","journal-title":"Ir J Psychol Med."},{"issue":"2","key":"1103_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.0b013e3181e7f2ab","volume":"75","author":"NL Campbell","year":"2010","unstructured":"Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75(2):152\u20139.","journal-title":"Neurology"},{"issue":"9","key":"1103_CR65","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/bcp.13976","volume":"85","author":"SW Narayan","year":"2019","unstructured":"Narayan SW, Pearson SA, Litchfield M, Le Couteur DG, Buckley N, McLachlan AJ, et al. Anticholinergic medicines use among older adults before and after initiating dementia medicines. Br J Clin Pharmacol. 2019;85(9):1957\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"1103_CR66","unstructured":"Feng Z, Gasdaska A, Wang J, Haltermann III W, Howard JM. Can integrated care models deliver better outcomes for dually eligible beneficiaries? Health Affairs Forefront. 2022."},{"key":"1103_CR67","unstructured":"National Institute for Health and Care Excellence: Guidelines. Dementia: Assessment, management and support for people living with dementia and their carers. London: National Institute for Health and Care Excellence (NICE) Copyright \u00a9 NICE 2018; 2018."},{"key":"1103_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1471-2318-13-121","volume":"13","author":"T Fi\u00df","year":"2013","unstructured":"Fi\u00df T, Thyrian JR, Wucherer D, A\u00dfmann G, Kilimann I, Teipel SJ, et al. Medication management for people with dementia in primary care: description of implementation in the DelpHi study. BMC Geriatr. 2013;13:121.","journal-title":"BMC Geriatr"},{"issue":"2","key":"1103_CR69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/11038120902978096","volume":"17","author":"G Johansson","year":"2010","unstructured":"Johansson G, Eklund K, Gosman-Hedstr\u00f6m G. Multidisciplinary team, working with elderly persons living in the community: a systematic literature review. Scand J Occup Ther. 2010;17(2):101\u201316.","journal-title":"Scand J Occup Ther."},{"issue":"5\u20136","key":"1103_CR70","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eurger.2017.07.019","volume":"8","author":"A Rojo-Sanch\u00eds","year":"2017","unstructured":"Rojo-Sanch\u00eds A, V\u00e9lez-D\u00edaz-Pallar\u00e9s M, Garc\u00eda MM, Silveira ED, Vicedo TB, Cruz-Jentoft A. Reduction of anticholinergic burden in older patients admitted to a multidisciplinary geriatric acute care unit. Eur Geriatr Med. 2017;8(5\u20136):492\u20135.","journal-title":"Eur Geriatr Med."},{"issue":"12","key":"1103_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009213","volume":"5","author":"HG van der Meer","year":"2015","unstructured":"van der Meer HG, Wouters H, van Hulten R, Pras N, Taxis K. Decreasing the load? Is a multidisciplinary multistep medication review in older people an effective intervention to reduce a patient\u2019s drug burden index? Protocol of a randomised controlled trial. BMJ Open. 2015;5(12): e009213.","journal-title":"BMJ Open"},{"issue":"19","key":"1103_CR72","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jama.2012.36918","volume":"308","author":"LN Gitlin","year":"2012","unstructured":"Gitlin LN, Kales HC, Lyketsos CG. Managing behavioral symptoms in dementia using nonpharmacologic approaches: an overview. JAMA. 2012;308(19):2020.","journal-title":"JAMA"},{"issue":"12","key":"1103_CR73","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/jgs.13807","volume":"63","author":"JT Hanlon","year":"2015","unstructured":"Hanlon JT, Semla TP, Schmader KE. Alternative medications for medications in the use of high-risk medications in the elderly and potentially harmful drug-disease interactions in the elderly quality measures. J Am Geriatr Soc. 2015;63(12):e8\u201318.","journal-title":"J Am Geriatr Soc"},{"key":"1103_CR74","unstructured":"Reuben DB, Herr KA, Pacala JT, Pollock BG, Potter JF, Semla TP. Geriatrics at your fingertips: American Geriatrics Society; 2016."},{"issue":"1","key":"1103_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007488","volume":"5","author":"I Abraha","year":"2015","unstructured":"Abraha I, Cruz-Jentoft A, Soiza RL, O\u2019Mahony D, Cherubini A. Evidence of and recommendations for non-pharmacological interventions for common geriatric conditions: the SENATOR-ONTOP systematic review protocol. BMJ Open. 2015;5(1): e007488.","journal-title":"BMJ Open"},{"issue":"6","key":"1103_CR76","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jamda.2011.12.059","volume":"13","author":"DP Seitz","year":"2012","unstructured":"Seitz DP, Brisbin S, Herrmann N, Rapoport MJ, Wilson K, Gill SS, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012;13(6):503\u20136 (e2).","journal-title":"J Am Med Dir Assoc"},{"key":"1103_CR77","unstructured":"O'Neil ME, Freeman M, Christensen V, Telerant R, Addleman A, Kansagara D. A systematic evidence review of non-pharmacological interventions for behavioral symptoms of dementia. Washington (DC): Department of Veterans Affairs (US); 2011."},{"issue":"6","key":"1103_CR78","first-page":"195","volume":"29","author":"C Siders","year":"2004","unstructured":"Siders C, Nelson A, Brown LM, Joseph I, Algase D, Beattie E, et al. Evidence for implementing nonpharmacological interventions for wandering. Rehabil Nurs. 2004;29(6):195\u2013206.","journal-title":"Rehabil Nurs"},{"issue":"1","key":"1103_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2045-7022-1-11","volume":"1","author":"V Cardona","year":"2011","unstructured":"Cardona V, Guilarte M, Luengo O, Labrador-Horrillo M, Sala-Cunill A, Garriga T. Allergic diseases in the elderly. Clin Transl Allergy. 2011;1(1):11.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"1103_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1398-9995.2007.01594.x","volume":"63","author":"J Bousquet","year":"2008","unstructured":"Bousquet J, Bieber T, Fokkens W, Humbert M, Kowalski ML, Niggemann B, et al. Consensus statements, evidence-based medicine and guidelines in allergic diseases. Allergy. 2008;63(1):1\u20134.","journal-title":"Allergy"},{"issue":"21","key":"1103_CR81","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/CIR.0b013e31821daaf6","volume":"123","author":"WS Aronow","year":"2011","unstructured":"Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF\/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434\u2013506.","journal-title":"Circulation"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01103-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01103-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01103-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:48:21Z","timestamp":1713282501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01103-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01103-2","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"21 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or in preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Rajender R. Aparasu has received research funding from Astellas Inc., Incyte Corp., Gilead, and Novartis Inc. for projects unrelated to the current work. Ashna Talwar, Satabdi Chatterjee, Susan Abughosh, Jeffrey Sherer, and Michael Johnson have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was approved by the University of Houston Committee for the Protection of Human Subjects under the exempt category.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data on which this study is based are not available due to the CMS data use restrictions for research identifiable files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: All authors. Acquisition of data: Ashna Talwar and Rajender R. Aparasu. Data analysis: Ashna Talwar. Data interpretation: All authors. Writing\u2014original draft: Ashna Talwar. Writing\u2014review &editing: All authors. Supervision: Rajender R. Aparasu.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}